The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
UPM-Kymmene Oyj
SWB:RPL
|
FI |
|
Somatic Systems Inc
OTC:SMAS
|
US |
|
C
|
City View Green Holdings Inc
CNSX:CVGR
|
CA |
|
C
|
Carson River Ventures Corp
CNSX:CRIV
|
CA |
|
Tmp Group SpA
F:A72
|
IT |
|
Puuilo Oyj
F:8JQ
|
FI |
|
G
|
Gwo Xi Stem Cell Applied Technology Co Ltd
TPEX:6704
|
TW |
|
G
|
Genesis Fertility Center PCL
SET:GFC
|
TH |
|
A
|
Alefarm Brewing A/S
F:902
|
DK |
|
B
|
Budweiser Brewing Company APAC Ltd
OTC:BDWBF
|
HK |
|
E
|
Ecora Royalties PLC
F:HGR
|
UK |
|
F
|
Fortuna Metals Ltd
F:TG5
|
AU |
|
Steel Pipe Industry of Indonesia Tbk PT
IDX:ISSP
|
ID |
|
T
|
Tennant Minerals Ltd
ASX:TMS
|
AU |
|
O
|
Olympus Corp
SWB:OLY1
|
JP |
|
H
|
Hong Kong Food Investment Holdings Ltd
HKEX:60
|
HK |
|
L
|
LaserOptek Co Ltd
KOSDAQ:199550
|
KR |
|
R
|
Rio Tinto PLC
F:RIOA
|
UK |
|
CorVel Corp
NASDAQ:CRVL
|
US |
|
B
|
Bank Maybank Indonesia Tbk PT
XMUN:BOZA
|
ID |
UPM-Kymmene Oyj (RPL)’s 12-month stock price forecast through July 2027 has a consensus target of €27.59, implying 24% upside. The forecast is based on price targets from 20 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
RPL is 27.59 EUR with a low forecast of 21.33 EUR and a high forecast of 31.68 EUR.
Over the last 13 years, the compound annual growth rate for Revenue has been -1%. The projected CAGR for the next 8 years is 1%.
Over the last 13 years, the compound annual growth rate for Gross Profit has been -1%. The projected CAGR for the next 3 years is -19%.
Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 8 years is 13%.
The compound annual growth rate for Pre-Tax Income over the next 3 years is 23%.
The compound annual growth rate for Net Income over the next 5 years is 19%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more